CE-Ventures invests $60m in UK biotech Oyster Therapeutics

Published · Updated · Based on reporting by Wamda

UK-based Oyster Therapeutics has secured $60 million in Series A funding. CE-Ventures, the corporate venture arm of UAE's Crescent Enterprises, participated in the round. The company focuses on targeted protein degradation therapies for neurodegenerative conditions like Alzheimer's disease.

Why it matters

The investment highlights growing interest in deep tech solutions for brain disorders.

Read the full coverage

More on: Space & Science · Startups & Funding · Middle East

This brief was written with AI from the headlines and excerpts published by the outlets above, and may contain errors. Follow the links for the original reporting.